Insart-CC Tablet is a combination antihypertensive medication containing Telmisartan 40 mg, Cilnidipine 10 mg, and Chlorthalidone 12.5 mg, formulated to effectively manage hypertension. Telmisartan, an angiotensin II receptor blocker (ARB), works by inhibiting the vasoconstrictive effects of angiotensin II, thereby reducing peripheral vascular resistance and lowering blood pressure. Cilnidipine, a calcium channel blocker of the dihydropyridine class, exerts vasodilatory effects by inhibiting L-type and N-type calcium channels, leading to decreased arterial stiffness and improved vascular compliance. Chlorthalidone, a thiazide-like diuretic, promotes natriuresis and diuresis by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, contributing to volume reduction and further blood pressure control. The combination of these three agents offers complementary mechanisms of action, enhancing antihypertensive efficacy while minimizing adverse effects associated with higher doses of individual drugs. Insart-CC is indicated for patients with essential hypertension who require multi-drug therapy to achieve optimal blood pressure targets. It is essential to monitor electrolyte levels, renal function, and blood pressure regularly during treatment. This combination therapy should be used under medical supervision, considering contraindications such as hypersensitivity to any component, severe renal impairment, or pregnancy.